Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cepheid Announces Chlamydia and N. gonorrhoeae Test Categorized 'Moderate Complexity' by FDA

Published: Tuesday, January 22, 2013
Last Updated: Tuesday, January 22, 2013
Bookmark and Share
The test runs on Cepheid's GeneXpert® Systems and is the first and only molecular CT/NG test to be categorized as Moderately Complex.

Cepheid announced the U.S. Food & Drug Administration (FDA) has categorized Cepheid's Xpert® CT/NG test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA). Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The test runs on Cepheid's GeneXpert® Systems and is the first and only molecular CT/NG test to be categorized as Moderately Complex. The Moderately Complex categorization will now allow the accuracy benefits of molecular diagnostics to be realized over a broader testing universe.

"In a recent study of 23 developed countries by the Institute of Medicine and the National Research Council, the U.S. was found to have the highest rates of Sexually Transmitted Diseases among youths," said John Bishop, Cepheid's Chief Executive Officer. "Now accessible to more than 20,000 Moderately Complex U.S. labs and 7,000 High Complexity U.S. labs, Xpert CT/NG becomes an important new weapon in reducing STD rates as clinicians can test, consult with, and treat their patients on a more timely basis."

"The classification of Xpert CT/NG by the FDA as 'Moderate Complexity' is a breakthrough for sexual health and STD prevention. The large number of Moderate Complexity point-of-care laboratories that exist in U.S. hospitals and clinics can now offer rapid, highly accurate and private same-day STD testing," said Jeffrey D. Klausner, MD, MPH, Professor of Medicine, UCLA-David Geffen School of Medicine. "Public health officials need to work with providers to increase the availability of those tests. Faster STD detection and treatment could go a long way in stemming the continued epidemic of STDs in the United States."

Gonorrhea and Chlamydia are Sexually Transmitted Diseases. Both are easily treated when detected and managed quickly. Chlamydia remains the most common sexually transmitted bacterial infection in the United States. While the CDC recommends annual testing for all sexually active women aged 25 and under, their most recent nationally representative estimate among this population found that only 38 percent of sexually active women were tested for chlamydia during the previous year.

Gonorrhea is the second most commonly reported bacterial infectious disease in the country. The CDC estimates that more than 700,000 Americans become infected with gonorrhea every year, yet fewer than half of these infections are diagnosed and reported to the CDC. Current testing protocols for Neisseria gonorrhoeae are often problematic due to cross-reactivity with other organisms, often requiring an additional confirmatory test. These delays and coordination issues can significantly hamper communication and consultation, leaving both patients and their partners uninformed and untreated.

The categorization of commercially marketed in vitro diagnostic tests under CLIA is the responsibility of the FDA. This categorization includes the process of assigning commercially marketed in vitro diagnostic test systems to one of three CLIA regulatory categories:

•    waived tests
•    tests of moderate complexity
•    tests of high complexity

Cepheid was the first company to receive a 'Moderate Complexity' categorization for a nucleic acid test and Xpert CT/NG is the 12th Cepheid test to be categorized as such.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rapid Flu/RSV Test Obtains CE Mark
Cepheid's Xpert Xpress test for influenza and respiratory syncytial virus receives CE-mark.
Monday, October 31, 2016
Danaher’s Cepheid Acquisition Receives Required Regulatory Clearances
Cepheid announced that antitrust clearances have been received or the requisite waiting periods have expired, as applicable.
Monday, October 24, 2016
FDA Supports Expanded Claims for Xpert Carba-R Test for "Superbugs"
Xpert Carba-R test is the first FDA-cleared molecular test for rapid detection of carbapenemase producing organisms directly from rectal swab specimens.
Saturday, July 02, 2016
Cepheid Announces Partnership with Medline
Company has announced partnership with Medline for the distribution of the GeneXpert® System.
Saturday, April 23, 2016
Cepheid's Next-Gen MRSA Test Gets CE Mark
The number one, on-demand molecular test for MRSA colonization is now improved.
Tuesday, April 05, 2016
Cepheid Receives FDA Clearance for Xpert Norovirus
Xpert Norovirus is the first on-demand molecular test for detection of Norovirus, providing accurate Norovirus detection in as little as one hour.
Monday, December 01, 2014
Cepheid Awarded Funding To Develop Xpert Ebola
With Funding from the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, Cepheid expects to deliver prototype in as little as eight weeks.
Friday, November 14, 2014
Cepheid Reports Q4 Full Year 2013 Results
Company reports revenues for Q4 2013 of $113.3 million.
Monday, February 03, 2014
Cepheid to Sponsor BASHH 2013 Spring Meeting
Cepheid is helping to bring together prominent scientists and clinicians from across the UK at the British Association for Sexual Health and HIV (BASHH) 2013 Spring Meeting.
Tuesday, May 07, 2013
Cepheid and FIND Announce Collaboration to Develop HIV Viral Load Test
Company’s collaborate to accelerate the development of a rapid molecular test for the measurement of human immunodeficiency virus viral load.
Wednesday, February 09, 2011
Cepheid Announces European Release of Test for Simultaneous Detection of MTB and Resistance to Rifampicin
Company’s GeneXpert® system capabilities enable new TB diagnostic tool.
Monday, May 04, 2009
Cepheid's Xpert™ MRSA PCR-Based Drug Resistant Test Receives FDA Clearance
The US FDA has cleared a Cepheid’s PCR test which is designed to detect nosocomial and antibiotic-resistant strain of Staphylococcus in over one hour.
Thursday, April 19, 2007
Cepheid Acquires Sangtec Molecular for $27 Million
Cepheid expands its PCR based molecular diagnostics product area by acquiring Sangtec Molecular Diagnostics AB from the Nycomed-owned ALTANA Pharma AG.
Friday, February 16, 2007
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
BGI Sequences Gingko Tree, Revealing Large, Highly Repetitive Genome
Researchers at BGI have sequenced the more than 10-gigabase ginkgo genome to find a high number of repetitive sequences as well as a number of gene clusters that appear to be involved in defense mechanisms.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!